Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2017 and Fruquintinib in Advanced Colorectal Cancer
NCT07621159Phase 2Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Jul 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HDM2017 in colorectal cancer (CRC), sponsored by Huadong Medicine. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
HDM2017
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07621159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621159.